Brainomix

Brainomix Teams With PFF to Test AI Lung CT Analysis With Patients

Image
Brainomix Teams With PFF to Test AI Lung CT Analysis With Patients

Oxford – October 15, 2026 -- Brainomix has partnered with the Pulmonary Fibrosis Foundation (PFF) to test how patients and caregivers respond when its FDA-cleared, CE-marked e-Lung quantitative CT analysis is built into clinicians' assessment workflow for pulmonary fibrosis (PF) and other fibrotic interstitial lung diseases (ILD).

Patient research targets how CT metrics shape treatment conversations

The multi-phase initiative will examine how objective quantitative CT metrics could improve clinicians' understanding of disease change over time. It will also assess how patients experience and understand those insights.

Brainomix Joins UK's Future Fifty Scale-Up Programme

Image
Brainomix Joins UK's Future Fifty Scale-Up Programme

Oxford – September 19, 2026 -- Brainomix, an Oxford-based AI-powered medical imaging company, has been selected to join Future Fifty, the UK's invitation-only scale-up programme run by Tech Nation and Founders Forum Group.

Brainomix joins 24 other companies in a cohort that has raised £1.47 billion collectively

The latest Future Fifty cohort spans 10 sectors including AI, healthtech, biotech, fintech, energy and advanced manufacturing, and employs more than 3,800 people across the group. The programme has previously supported 30% of all UK tech unicorns and 40% of the country's decacorns, including Revolut and Wise.